Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... UK (PRWEB) , ... July 27, 2015 , ... Production ... growth over the past few years in the EU. For instance, it surpassed the ... the EUR 92 million mark in 2010. Germany is a major producer, while Italy ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
(Date:7/27/2015)... ... 27, 2015 , ... BlueInGreen® announced the addition of EnviroSales ... the world’s most efficient gas dissolution technology to all of Florida, excluding the ... industrial and municipal markets. With offices located in Sarasota, Sebring and Melbourne Beach, ...
(Date:7/27/2015)... , July 27, 2015 The ... announced the winners of its annual Klerman and ... by scientists who have been supported by NARSAD ... scientists to pursue innovative ideas in neurobiological and ... of concept for the early detection, treatment, prevention ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Advocacy Groups Launch Joint Effort to Preserve Eyesight of,Millions At-Risk ... that eye exams are being,ignored by many aged over 40. ... the last year to have their eyes checked, even though,twice ... or early,death. The survey showed that awareness of glaucoma was ...
... CRVL ), a leading provider of workers, ... 150,000 facility and,provider locations to its national CorCare ... provider network additions are the,result of a new ... Petersburg, FL. With more than 5,500 hospitals ...
... Time-Saving, ATLANTA, Oct. 1 Harmonex ... a revolutionary software platform,designed to assess children, ... CliniCom(TM), an intuitive, computer assisted intake and ... settings, gathers information,directly from patients and their ...
Cached Biology Technology:International Survey Shows People Over Forty Ignore Risk of Blindness 2International Survey Shows People Over Forty Ignore Risk of Blindness 3International Survey Shows People Over Forty Ignore Risk of Blindness 4International Survey Shows People Over Forty Ignore Risk of Blindness 5CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 2CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a prevalent fungal pathogen that causes 10,000 deaths per ... antifungal drugs by duplicating a section of one of ... yeast present in 80 percent of humans, is usually ... oral and vaginal infections (candiasis or thrush) that are ...
... at the Stanford University School of Medicine have taken ... cells that could eventually be transplanted into living organisms. ... surgical resident Oscar Abilez, MD, and colleagues have successfully ... building blocks of blood vessels, after placing them in ...
... technique of distraction has been researched and successfully applied ... with certain medical procedures. The use of distraction is ... psychological element in the perception of pain, with the ... the perception of the pain. , Distraction techniques ...
Cached Biology News:U of M researchers discover genetic key to treating deadly fungal infections 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3Virtual realities against pain 2
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: